Address correspondence to:
Prakash C. Deedwania, MD, FACC, FACP, FAHA
Chief, Cardiology Section
UCSF Program at Fresno
2615 E. Clinton Avenue (111)
Fresno, CA 93703
Telephone: 559-228-5325
Fax: 559-228-6961
Email: deed1@sbcglobal.net

Abstract: African American, Hispanic, South Asian, and Pima Indian populations are at high risk for cardiovascular mortality and morbidity, partly owing to greater prevalence of diabetes and obesity. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the treatment of choice for patients with diabetes at high risk for cardiovascular events. Early reports suggest dual renin-angiotensin system blockade is as effective as monotherapy in high-risk patients; further studies will determine if it increases cardioprotective effects in patients with chronic kidney disease, diabetes, and heart failure.

Key Words: Ethnicity, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, diabetes, cardioprotection

Disclosure: Dr. Deedwania is a consultant for Boehringer Ingelheim, a consultant/speaker for AstraZeneca, and a consultant/speaker for Novartis. Mary Ellen Shepard, Clinical CONNEXION (Newtown, Pennsylvania), provided editorial assistance. Boehringer Ingelheim Pharmaceuticals, Inc. provided editorial support. This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc.


Continue Reading